Literature DB >> 8398309

Increased chemosensitivity to doxorubicin of intrinsically multidrug-resistant human colon carcinoma cells by prolonged exposure to verapamil.

G Toffoli1, L Tumiotto, M Gigante, M G Dall'Arche, T Perin, M Boiocchi.   

Abstract

Resistance modifying agents (RMA) such as verapamil (VER) have proved effective in reversing multidrug resistance (MDR) in many in vitro experimental models, but clinical results with RMA have been disappointing. To clarify this apparent discrepancy we have evaluated the cytotoxic effects of doxorubicin (DOX) plus VER in four human colon carcinoma (HCOC) cell lines (LoVo, DLD-1, SW948, SW1116). These lines were selected on the basis of their levels of mdr1 mRNA being similar to those expressed by HCC obtained from non-drug-treated patients. In all cell lines the sensitising effect of VER on DOX cytotoxicity was schedule-dependent and maximal potentiation of DOX cytotoxicity was obtained by exposure to VER for a time > or = the cells' population doubling time.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8398309     DOI: 10.1016/0959-8049(93)90123-w

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  3 in total

1.  Multidrug resistance circumvention by a new triazinoaminopiperidine derivative S9788 in vitro: definition of the optimal schedule and comparison with verapamil.

Authors:  A M Julia; H Roché; M Berlion; C Lucas; G Milano; J Robert; J P Bizzari; P Canal
Journal:  Br J Cancer       Date:  1994-05       Impact factor: 7.640

2.  Pharmacokinetics of doxorubicin co-administered with high-dose verapamil.

Authors:  M Gigante; G Toffoli; M Boiocchi
Journal:  Br J Cancer       Date:  1995-01       Impact factor: 7.640

Review 3.  Cellular Mechanisms Accounting for the Refractoriness of Colorectal Carcinoma to Pharmacological Treatment.

Authors:  Jose J G Marin; Rocio I R Macias; Maria J Monte; Elisa Herraez; Ana Peleteiro-Vigil; Beatriz Sanchez de Blas; Paula Sanchon-Sanchez; Alvaro G Temprano; Ricardo A Espinosa-Escudero; Elisa Lozano; Oscar Briz; Marta R Romero
Journal:  Cancers (Basel)       Date:  2020-09-11       Impact factor: 6.639

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.